Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report released on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners cut their price objective on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, August 14th.

Aspira Women’s Health Trading Down 2.7 %

NASDAQ AWH opened at $0.79 on Wednesday. Aspira Women’s Health has a 12 month low of $0.74 and a 12 month high of $6.01. The stock has a market cap of $12.66 million, a price-to-earnings ratio of -0.54 and a beta of 1.48. The company’s 50 day moving average is $1.04 and its two-hundred day moving average is $1.95.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period in the prior year, the business earned ($0.28) earnings per share. Sell-side analysts forecast that Aspira Women’s Health will post -1.26 EPS for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.